Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Thyroid Neoplasms 1Skin Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Leukemia 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

Gemcitabine 100130-nm albumin-bound paclitaxel 34Oxaliplatin 28Capecitabine 27Fluorouracil 25Albumin-Bound Paclitaxel 23Leucovorin 19Irinotecan 18Erlotinib Hydrochloride 14Cyclophosphamide 12Radiosurgery 11pembrolizumab 10Radiotherapy 10Nivolumab 10Bevacizumab 10Surgical Procedures, Operative 9avelumab 7Docetaxel 7Taxes 6Cisplatin 6ruxolitinib 5folfirinox 5Specimen Handling 5Paclitaxel 5Everolimus 5Cetuximab 5ALT-803 5trametinib 4spartalizumab 4fludarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Pancreatic Neoplasms × Interleukin-15 × Clear all
NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NantCell, Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡